Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.35 HKD
789.00 M HKD
6.56 B HKD
501.45 M
About HUTCHMED (CHINA) LIMITED
Sector
CEO
Wei Guo Su
Headquarters
Hong Kong
Website
Founded
2000
FIGI
BBG011J3CPR1
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.
HCM Learning experiencePlaying Trading Simulator:
Big time rookie mistake.
Bought 350 shares at $41.71 on 3JAN18. Price was falling.
Same day bought 500 shares at $39.93 in order to dilute my buying price.
I began studying the chart and saw my mistake.
On 5JAN18 I sold my shares using a trailing stop of 10 cents.
It exe
Tracking HCMI've been a long term holder of HCM since 2009. They are also listed on the FTSE AIM 100 LSE:HCM.
They have outperformed the NASDAQ BIOTECHNOLOGY INDEX INDEX:NBI
Now would be a good place to exit.
I will continue to hold for now, i am not trading this. It's included in my long term portfolio.
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 13 is 22.40 HKD — it has increased by 0.67% in the past 24 hours. Watch HUTCHMED (CHINA) LIMITED stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on HKEX exchange HUTCHMED (CHINA) LIMITED stocks are traded under the ticker 13.
13 stock has fallen by −4.68% compared to the previous week, the month change is a −20.85% fall, over the last year HUTCHMED (CHINA) LIMITED has showed a −15.15% decrease.
We've gathered analysts' opinions on HUTCHMED (CHINA) LIMITED future price: according to them, 13 price has a max estimate of 62.79 HKD and a min estimate of 35.40 HKD. Watch 13 chart and read a more detailed HUTCHMED (CHINA) LIMITED stock forecast: see what analysts think of HUTCHMED (CHINA) LIMITED and suggest that you do with its stocks.
13 stock is 2.97% volatile and has beta coefficient of 1.08. Track HUTCHMED (CHINA) LIMITED stock price on the chart and check out the list of the most volatile stocks — is HUTCHMED (CHINA) LIMITED there?
Today HUTCHMED (CHINA) LIMITED has the market capitalization of 19.52 B, it has decreased by −4.30% over the last week.
Yes, you can track HUTCHMED (CHINA) LIMITED financials in yearly and quarterly reports right on TradingView.
HUTCHMED (CHINA) LIMITED is going to release the next earnings report on Feb 27, 2025. Keep track of upcoming events with our Earnings Calendar.
13 earnings for the last half-year are 0.23 HKD per share, whereas the estimation was −0.61 HKD, resulting in a 138.22% surprise. The estimated earnings for the next half-year are −0.07 HKD per share. See more details about HUTCHMED (CHINA) LIMITED earnings.
HUTCHMED (CHINA) LIMITED revenue for the last half-year amounts to 2.39 B HKD, despite the estimated figure of 2.49 B HKD. In the next half-year revenue is expected to reach 2.98 B HKD.
13 net income for the last half-year is 201.74 M HKD, while the previous report showed −529.92 M HKD of net income which accounts for 138.07% change. Track more HUTCHMED (CHINA) LIMITED financial stats to get the full picture.
No, 13 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 25, 2024, the company has 1.99 K employees. See our rating of the largest employees — is HUTCHMED (CHINA) LIMITED on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. HUTCHMED (CHINA) LIMITED EBITDA is −861.31 M HKD, and current EBITDA margin is 3.05%. See more stats in HUTCHMED (CHINA) LIMITED financial statements.
Like other stocks, 13 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade HUTCHMED (CHINA) LIMITED stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So HUTCHMED (CHINA) LIMITED technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating HUTCHMED (CHINA) LIMITED stock shows the sell signal. See more of HUTCHMED (CHINA) LIMITED technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.